Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Pain 1Neoplasms 1Lymphoma, Mantle-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × Complementary Therapies × Clear all
NCT00003486 2013-07-10

Antineoplaston Therapy in Treating Patients With Colon Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡